A new treatment has been approved for pancreatic adenocarcinoma, a common form of pancreatic cancer. This treatment, a once-daily tablet, targets a key protein involved in tumor growth. It has shown promising results in clinical trials, improving survival rates for patients with previously treated metastatic pancreatic adenocarcinoma.

The treatment's approval came ahead of schedule. Further details about the treatment and its effects are available.

The approval marks a significant development in the treatment of this form of cancer, which arises from cells lining the pancreas.